Merck shares results for Keytruda in cervical cancer treatment

Betsy Goodfellow | March 18, 2024 | News story | Research and Development Merck, Oncology, cervical cancer, keytruda, women's health 

Merck, known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-A18 trial, which investigates Keytruda in combination with chemoradiotherapy for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer.

The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival in this indication, with the drug’s safety profile remaining consistent with previously observed safety information and no new safety signals being identified.

It is expected that the full results will be presented at an upcoming medical meeting as well as being shared with the relevant global regulatory authorities.

Advertisement

Dr Gursel Aktan, vice president, global clinical development at Merck Research Laboratories, commented: “This is the first phase 3 trial in which an immunotherapy-based regimen has shown a statistically significant and clinically meaningful improvement in overall survival compared to chemoradiotherapy alone. Building on the positive progression-free survival findings from this study, these results underscore our commitment to exploring the role of Keytruda across different types of cancers in earlier stages of disease, where there is a greater potential for better outcomes.”

Betsy Goodfellow

Related Content

Universal Quantum partners with Open Quantum Institute to tackle endometriosis with new technology

Based in Brighton, UK, Universal Quantum has joined the Open Quantum Institute (OQI) to explore …

Cervical cancer experts campaign to increase screening rates and save lives

A coalition of experts fighting to end cervical cancer, referred to as the UK Consensus …

Theramex receives recommendation for YSELTY in Scotland

Theramex, a dedicated women’s health company, have announced that the Scottish Medicines Consortium (SMC) have …

The Gateway to Local Adoption Series

Latest content